350 related articles for article (PubMed ID: 24033666)
21. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
22. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
Tseng D; Rachakonda LP; Su Z; Advani R; Horning S; Hoppe RT; Quon A; Graves EE; Loo BW; Tran PT
Radiat Oncol; 2012 Jan; 7():5. PubMed ID: 22260710
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study.
Durmo R; Donati B; Rebaud L; Cottereau AS; Ruffini A; Nizzoli ME; Ciavarella S; Vegliante MC; Nioche C; Meignan M; Merli F; Versari A; Ciarrocchi A; Buvat I; Luminari S
Hematol Oncol; 2022 Oct; 40(4):645-657. PubMed ID: 35606338
[TBL] [Abstract][Full Text] [Related]
24. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18 F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma.
Mouheb M; Pierre-Jean M; Devillers A; Fermé C; Benchalal M; Manson G; Le Jeune F; Houot R; Palard-Novello X
Clin Nucl Med; 2024 Jan; 49(1):e1-e5. PubMed ID: 38015041
[TBL] [Abstract][Full Text] [Related]
26. The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.
Burger IA; Vargas HA; Goldman DA; Gonen M; Kumar A; Zelenetz AD; Schöder H; Hricak H
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):701-7. PubMed ID: 23389428
[TBL] [Abstract][Full Text] [Related]
27. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
28. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.
Smith CP; Adefres B; Chang EM; Huang TQ; Parikh N; Raldow A
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e992-e999. PubMed ID: 35963771
[TBL] [Abstract][Full Text] [Related]
31. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
32. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
33. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
[TBL] [Abstract][Full Text] [Related]
34. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
35. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
36. Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.
Orlacchio A; Schillaci O; Gaspari E; Della Gatta F; Danieli R; Bolacchi F; Ragano Caracciolo C; Mancini A; Simonetti G
Radiol Med; 2012 Oct; 117(7):1250-63. PubMed ID: 22327919
[TBL] [Abstract][Full Text] [Related]
37. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
38. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JO; Lee HS; Lee SM; Lee GW; Lee SE; Kim SJ
Cancer Sci; 2012 Mar; 103(3):477-82. PubMed ID: 22126515
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
